Dupixent clears PhIII trial in new disease as blockbuster looks to expand past Regeneron-Sanofi split

Sanofi and Regeneron may be splitting up, but their billion-dollar baby, Dupixent, keeps on growing.

Already grossing over $2 billion last year based on FDA approvals for asthma and atopic dermatitis, Dupixent may be nearing a third indication: Eosinophilic esophagitis (EoE), an inflammatory disease marked by the buildup of white blood cells in the esophagus and which affects around 160,000 US patients annually.